Ofatumumab in Relapsed Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL).
Phase of Trial: Phase II
Latest Information Update: 08 Dec 2015
At a glance
- Drugs Ofatumumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 08 Dec 2015 Results presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 25 Jul 2011 Planned end date (May 2013) added as reported by ClinicalTrials.gov.
- 13 May 2011 Actual initiation date (1 May 2011) added as reported by ClinicalTrials.gov.